CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Authors
H-T Arkenau
Y-J Bang
+21 more
HA Burris
HC Chung
JS de Bono
S Decordova
MP DeYoung
JP Eder
G Ganji
S-W Han
JR Infante
S Kalyana-Sundaram
R Kumar
C Lemech
J Mateo
M Motwani
SY Rha
S Sharma
DA Smith
K Swales
JM Tolson
J Wu
L Yan
Publication date
1 October 2017
Publisher
'American Association for Cancer Research (AACR)'
Doi
Cite
Abstract
Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of pan-PI3K inhibitors. GSK2636771 is a potent, orally bioavailable, adenosine triphosphate-competitive, selective inhibitor of PI3Kβ.Methods: We evaluated the safety, pharmacokinetics, pharmacodynamics and antitumor activity of GSK2636771 to define the recommended phase II dose (RP2D). During the dose-selection and dose-escalation stages (parts 1 and 2), patients with PTEN-deficient advanced solid tumors received escalating doses of GSK2636771 (25-500 mg once daily) using a modified 3+3 design to determine the RP2D; tumor type-specific expansion cohorts (part 3) were implemented to further assess tumor responses at the RP2D.Results: A total of 65 patients were enrolled; dose-limiting toxicities were hypophosphatemia and hypocalcemia. Adverse events included diarrhea (48%), nausea (40%), and vomiting (31%). Single- and repeat-dose exposure increased generally dose proportionally. GSK2636771 400 mg once daily was the RP2D. Phospho/total AKT ratio decreased with GSK2636771 in tumor and surrogate tissue. A castrate-resistant prostate cancer (CRPC) patient harboring PIK3CB amplification had a partial response for over a year; an additional 10 patients derived durable (≥24 weeks) clinical benefit, including two other patients with CRPC with PIK3CB alterations (≥34 weeks). GSK2636771 400 mg once daily orally induced sufficient exposure and target inhibition with a manageable safety profile.Conclusions: Genomic aberrations of PIK3CB may be associated with clinical benefit from GSK2636771. Clin Cancer Res; 23(19); 5981-92. ©2017 AACR
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1158%2F1078-0432.c...
Last time updated on 04/12/2020
UCL Discovery
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.ucl.ac.uk.OAI2:100...
Last time updated on 31/05/2019
Institute of Cancer Research Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:repository.icr.ac.uk:inter...
Last time updated on 20/11/2019
SNU Open Repository and Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:s-space.snu.ac.kr:10371/17...
Last time updated on 28/03/2021